ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2014
The significance of YKL-40 protein in liver fibrosis.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 55 citations in OpenAlex.
- Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.Journal of viral hepatitis · 2026Trial
- Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.Frontiers in immunology · 2023Trial
- Thyroid function and hepatic fibrosis/cirrhosis: a two-sample Mendelian randomization study.Frontiers in genetics · 2025Article
- Chitinase 3-like protein 1 deficiency ameliorates drug-induced acute liver injury by inhibition of neutrophil recruitment through lipocalin-2.Frontiers in pharmacology · 2025Article
- New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?Journal of personalized medicine · 2024Review
- Potential Roles and Future Perspectives of Chitinase 3-like 1 in Macrophage Polarization and the Development of Diseases.International journal of molecular sciences · 2023Review
- Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.Biological research · 2023Article
- Association of Non-Invasive Markers with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.Annals of translational medicine · 2021Article
- The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases.Journal of clinical laboratory analysis · 2020Article
- Article
- Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine.BMC endocrine disorders · 2017Article
- Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan.International journal of medical sciences · 2017Article
- Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aims of this review are to describe the present knowledge about YKL-40 protein, discuss its relation to liver fibrosis, and to look ahead at future perspectives of YKL-40 research.
introductionLiver fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of hepatic stellate cells. Therefore, advancement in the identification of liver fibrosis biomarkers with diagnostic and prognostic values becomes an important tool for future molecular therapy. The molecular basis of YKL-40 in liver fibrosis is unknown.
methodsA PubMed database search was performed for studies of YKL-40 in liver injury and fibrosis. RESULTS AND
conclusionsYKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction by promoting chemotaxis, cell attachment and migration, reorganization, and tissue remodeling as a response to endothelial damage. Several studies demonstrate that elevated serum YKL-levels are independently associated with the presence of endothelial damage and even higher YKL-40 levels are documented in liver fibrosis. YKL-40 may play a key role in liver injury and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.